Changes in Beneficial Ownership · 4
Immunocore Holdings plc
Changes in Beneficial Ownership
Structured filing — 4
form4-05282026_070509.xml
Filing details
- Report period
- 2026-05-27
- Issuer
- Immunocore Holdings plc
- Issuer CIK
- 0001671927
- Trading symbol
- IMCR
Reporting owner 1
- Name
- Peterson Kristine
- Reporting owner CIK
- 0001508596
- Relationship
- Director
- Address
- C/O IMMUNOCORE HOLDINGS PLC, 92 PARK DRIVE, MILTON PARK, ABINGDON, UNITED KINGDOM, OXFORDSHIRE, X0, OX14 4RY
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy) | 28.52 | 2026-05-27 | A · Form 4 | 27,492 | A | 0 | [F1] | 2036-05-26 | Ordinary Shares | 27,492 | 27,492 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.↩ 1
Signature 1
- Signed
- /s/ Lily Hepworth, Attorney-in-Fact
- Date
- 2026-05-28
Company context
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.